2018 American Transplant Congress » Poster Session C: Liver: Immunosuppression and Rejection

6:00pm-7:00pm

A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report

T-.H. Wu, C-.H. Cheng, Y-.C. Wang, C-.F. Lee, T-.J. Wu, H. Chou, K-.M. Chan, W-.C. Lee.

6:00pm-7:00pm

Adjunctive Corticosteroid Immunosuppression Improves Hyperbilirubinemia Following Liver Transplantation (OLT)

G. Malat, D. Reich, G. Xiao, M. Harhay, K. Ranganna, D. Lee, S. Guy, S. Munoz.

6:00pm-7:00pm

Clinical Outcomes of Late Conversion to Once-Daily Tacrolimus after Liver Transplant

D. Kim,¹ Y. Jung,¹ J. Lee,¹ J. Lee,¹ S. Kim,² M. Ju,¹ M. Kim,¹ S. Kim,¹ D. Joo.¹

6:00pm-7:00pm

De Novo Use of Extended Released Tacrolimus (Meltdose, Envasus^R)) after OLT – Does the Colonic Resorption Influences the Outcome?

T. Soliman, G. Györi, M. Hofmann, A. Salat, S. Rockenschaub, G. Berlakovich.

6:00pm-7:00pm

Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review

M. Henry, M. Vacha.

6:00pm-7:00pm

Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus

M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹

6:00pm-7:00pm

Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis

R. Deng, B. Huang, Y. Shi, Y. Ma.

6:00pm-7:00pm

Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation-

Y. Yamada,¹ K. Hoshino,¹ M. Shinoda,¹ H. Obara,¹ S. Uemoto,³ T. Kaido,³ H. Okajima,³ T. Yagi,⁴ T. Yoshizumi,⁵ Y. Inomata,⁶ T. Hibi,⁶ K. Kubota,⁷ T. Suzuki,⁸ Y. Kitagawa,¹ H. Egawa,² T. Kuroda.¹

6:00pm-7:00pm

Side Effect Profile of Everolimus in Liver Transplant Patients

F. Kumssa, O. Sadiq, M. Alimirah, R. Kaur, A. Patel, S-.M. Jafri.

6:00pm-7:00pm

Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation

H. Egawa,¹ Y. Kotera,¹ A. Ohmori,¹ S. Yamashita,¹ T. Kato,¹ S. Nemoto,¹ T. Ishizuka,² M. Yamamoto.¹

6:00pm-7:00pm

The Efficacy of Low Dose Steroid Therapy for Postoperative Hyperbilirubinemia in Liver Transplant Recipients: A Prospective Randomized Controlled Trial

J. Yang, X. He, L. Wu, Z. Guo.

6:00pm-7:00pm

The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients

M. Del Gaudio,¹ M. Cescon,¹ M. Ravaioli,¹ V. Bertuzzo,¹ C. Zanfi,¹ M. Serenari,¹ L. Maroni,¹ C. Morelli,² A. Pinna.¹

6:00pm-7:00pm

The Net State of Immunosuppression in Septuagenarian Liver Transplant Recipients: Balancing Rejection and Infection Risks

J. Casale,¹ J. Clark,¹ B. Ravichandran,¹ J. LaMattina.²